

1. Jerome Groopman, "The Right to a Trial," *The New Yorker*, December 11, 2006, http://www.newyorker.com/archive/2006/12/18/061218fa_fact
2. Stephen R. Kovatis, "Do the Terminally Ill Have a Constitutional Right to Use Experimental Drugs?" *Temple Journal of Sci. Tech. & Envtl. Law*, vol. XXVI, <http://www.temple.edu/law/tjstel/2007/spring/v26no1-Kovatis.pdf>
3. Groopman, "The Right to a Trial."
4. *Id.*
5. "Cancer Data for the United States," Center for Disease Control, May 2013, <http://www.cdc.gov/nchs/fastats/cancer.htm>
6. Gregory Conko, "Sick Patients Need Cutting-Edge Drugs," *Wall Street Journal*, August 23, 2008, <http://online.wsj.com/article/SB121944789005365195.html>
7. *Id.*
8. "2013 Profile Biopharmaceutical Research Industry," PhRMA, 2013, <http://www.phrma.org/sites/default/files/pdf/PhRMA%20Profile%202013.pdf>
9. Investigational New Drug Application <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083533.pdf>
10. Wallace F. Janssen, "The Story Behind the Labels," *FDA Consumer*, June 1981, <http://www.fda.gov/AboutFDA/WhatWeDo/History/Overviews/ucm056044.htm>; "FY 2013 Budget Overview" Food and Drug Administration, <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/BudgetReports/UCM301719.pdf>
11. Pure Food and Drug Act of 1906, ch. 3915, 34 Stat. 769 (1906) (Repealed by the Federal Food, Drug, and Cosmetic Act of 1938), <http://www.fda.gov/regulatoryinformation/legislation/ucm148690.htm>; The Federal Food and Drugs Act of 1906 is referred to by some as the Wiley Act.
12. Federal Food and Drugs Act of 1906, Public Law Number 59-384, Section 1
13. John P. Swann, "FDA's Origin," 1998, <http://www.fda.gov/AboutFDA/WhatWeDo/History/Origin/ucm124403.htm>
14. Carol Ballentine, "Taste of Raspberries, Taste of Death: The 1937 Elixir Sulfanilamide Incident," *FDA Consumer Magazine*, June 1981, <http://www.fda.gov/AboutFDA/WhatWeDo/History/ProductRegulation/SulfanilamideDisaster/>
15. Juliana P. DeCarvalho, "Elixir Sulfanilamide," *Toxipedia*, July 7, 2013, <http://toxipedia.org/display/toxipedia/Elixir+Sulfanilamide>
16. *Id.*
17. Carol Ballentine, "Taste of Raspberries, Taste of Death: The 1937 Elixir Sulfanilamide Incident."
18. Food, Drug, and Cosmetic Act of 1938
19. Kefauver-Harris Drug Amendments to the FFDCA, P.L. 87-781, 1962.
20. Linda Bren, "Frances Oldham Kelsey: FDA Medical Reviewer Leaves Her Mark on History," *FDA Consumer Magazine*, March-April 2001, http://permanent.access.gpo.gov/lps1609/www.fda.gov/fdac/features/2001/201_kelsey.html
21. *Id.*
22. Susan Thaul, "How FDA Approves Drugs and Regulates Their Safety and Effectiveness," Congressional Research Service, May 18, 2012, <http://fpc.state.gov/documents/organization/191606.pdf>
23. 23??
24. Frank Lichtenberg, "The Impact of New Drug Launches on Longevity: Evidence From Longitudinal, Disease-Level Data from 52 Countries, 1982-2001," National Bureau of Economic Research, June 2003, http://www.nber.org/papers/w9754.pdf?new_window=1
25. "2013 Profile Biopharmaceutical Research Industry," PhRMA, 2013, <http://www.phrma.org/sites/default/files/pdf/PhRMA%20Profile%202013.pdf>; Two recent studies have placed the average cost for drug development over a billion dollars. The 2011 study by PhRMA placed the cost at \$1.3 billion (<http://www.phrma.org/drug-development-costs-have-increased>) and Deloitte found the average cost for drug development by the world's 12 largest drug manufacturers to be over one billion (Matthew

- Herper, "The Truly Staggering Cost of Inventing New Drugs" *Forbes*, February 10, 2012, <http://www.forbes.com/sites/matthewherper/2012/02/10/the-truly-staggering-cost-of-inventing-new-drugs/>). However, the California Biomedical Research Association found the cost to be much lower at only \$359 million. ("Fact Sheet New Drug Development Process" California Biomedical Research Association, <http://ca-biomed.org/pdf/media-kit/fact-sheets/cbradrugdevelop.pdf>).
26. "A National Survey of Orthopedic Surgeons Regarding the Food and Drug Administration and the Availability of New Therapies" Competitive Enterprise Institute, 2007, <http://cei.org/sites/default/files/The%20Polling%20Company%20-%20A%20National%20Survey%20of%20Orthopedic%20Surgeons%20Regarding%20the%20Food%20and%20Drug%20Administration%20and%20the%20Availability%20of%20New%20Therapies.pdf>
 27. "Investigational New Drug Application (IND)" FDA, <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083533.pdf>
 28. "Providing Access to Promising Therapies for Seriously Ill and Dying Patients," Testimony of Doctor Michael A. Friedman, Lead Deputy Commissioner of the Food and Drug Administration before the House Committee on Government Reform and Oversight, April 22, 1998, <http://www.fda.gov/NewsEvents/Testimony/ucm115120.htm>
 29. During all stages of human trials, the sponsor must obtain informed consent from all study participants. Informed consent includes the disclosure of all reasonably foreseeable risks and discomforts, any benefits that could reasonably be expected, and the availability of other appropriate courses of treatment. 21 CFR 50.25
 30. "The FDA's Drug Review Process: Ensuring Drugs are Safe and Effective" FDA, <http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm143534.htm>
 31. Michael Hay, Jesse Rosenthal, David Thomas, and John Craighead, "BIO/BioMedTracker Clinical Trial Success Rates Study," Biotechnology Industry Organization, February 15, 2011 <http://insidebioia.files.wordpress.com/2011/02/bio-ceo-biomedtracker-bio-study-handout-final-2-15-2011.pdf>
 32. During Phase II, researchers conduct a double-blind study to compare the results of the group receiving the investigational drug with a control group that receives either a placebo or the current medication approved to treat the condition in order to determine the efficacy of the investigational drug.
 33. Michael Hay, Jesse Rosenthal, David Thomas, and John Craighead, "BIO/BioMedTracker Clinical Trial Success Rates Study," Biotechnology Industry Organization, February 15, 2011.
 34. "Inside Clinical Trials: Testing Medical Products in People," FDA, <http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm143531.htm>
 35. While the CDER handles applications for new drugs, applications for the approval of new biologics are submitted to the FDA's Center for Biologics Evaluation and Research (CBER), and applications for new devices are submitted to the FDA's Center for Devices and Radiological Health (CDRH). The process used by these centers to approve new biologics and devices is very similar to the process used to approve new drugs. Because drugs represent the bulk of clinical trials, this paper is focused on the procedures used to approve new drugs.
 36. FY 2011 Performance Report to the President and Congress for the Prescription Drug User Fee Act, Food and Drug Administration, <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/UserFeeReports/PerformanceReports/PDUFA/UCM294101.pdf>
 37. FFDCA (P.L. 75-717, 1938), §505(c) and (d).
 38. Fran Hawthorne, *Inside the FDA: The Business and Politics Behind the Drugs We Take and the Food We Eat* (New Jersey: John Wiley & Sons, 2005).
 39. Catherine Arnst, "Dying Patients Fight the FDA," *Business Week*, July 25, 2007, <http://www.businessweek.com/stories/2007-07-25/dying-patients-fight-the-fdabusinessweek-business-news-stock-market-and-financial-advice>
 40. There was an informal "compassionate use" option that was theoretically available under which patients could request that the FDA, on a case-by-case basis, grant compassionate use of an

- investigational drug to an individual outside the clinical trial setting. There were no regulations governing this ad-hoc process, and there is no data available on how many people or for what conditions the FDA granted such access. Despite the fact that a small number of patients were granted access to investigational drugs without enrolling in a clinical trial, such exceptions were not the norm.
41. In June 1981, the CDC reported an unusual cluster of pneumocystis pneumonia exhibited by five homosexual men in Los Angeles, California. Over the ensuing months, the number of persons afflicted grew. The illness was originally called Gay Related Immune Deficiency (GRID) but after cases appeared in non-homosexual groups, including patients who received blood transfusions, hemophiliacs, and IV drug users, in August 1982, the CDC began using the new term Acquired Immune Deficiency Syndrome (AIDS).
 42. “Expanding Access to Investigational Therapies for HIV Infection and AIDS,” National Institute of Medicine, Roundtable for the Development of Drugs and Vaccines Against AIDS, 1991, <http://books.google.com/books?id=vN6J7u0lWvkC&pg=PA14&lpg=PA14&dq=fda+aids+access+to+investigationa+l+drugs&source=bl&ots=spnWpSzmAo&sig=wKfOclQGja0CSIZPelGLtzYzW2U&hl=en&sa=X&ei=mJ3yUZK6F4a0iwL88ID4Bw&ved=0CCkQ6AEwADgK#v=onepage&q=fda%20aids%20access%20to%20investigational%20drugs&f=false>
 43. Dale H. Gieringer, “Compassion vs Control: FDA Investigational-Drug Regulation,” Cato Institute, May 20, 1986, <http://www.cato.org/pubs/pas/pa072.html>
 44. *Id.*
 45. *Id.*
 46. There are similar expanded access programs for investigational devices. In the case of an investigational device, the application for expanded access is known as an Investigational Device Exemption (IDE).
 47. 21 U.S.C. 312.34
 48. *Id.*
 49. “Treatment IND,” Food and Drug Administration, April 16, 2009 <http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/PatientInvolvement/ucm123872.htm>
 50. Philip J. Hilts, *Protecting America’s Health: The FDA, Business, and One Hundred Years of Regulation* (New York: Alfred A. Knoph, 2003).
 51. “Expanding Access to Investigational Therapies for HIV Infection and AIDS,” National Institute of Medicine, Roundtable for the Development of Drugs and Vaccines Against AIDS, 1991, <http://books.google.com/books?id=vN6J7u0lWvkC&pg=PA14&lpg=PA14&dq=fda+aids+access+to+investigationa+l+drugs&source=bl&ots=spnWpSzmAo&sig=wKfOclQGja0CSIZPelGLtzYzW2U&hl=en&sa=X&ei=mJ3yUZK6F4a0iwL88ID4Bw&ved=0CCkQ6AEwADgK#v=onepage&q=fda%20aids%20access%20to%20investigational%20drugs&f=false>
 52. “SEER Cancer Statistics Review (CSR) 1975-2010” National Cancer Institute, June 14, 2013, http://seer.cancer.gov/csr/1975_2010/; “Cancer Facts & Figures 2012” American Cancer Society, 2012, <http://www.cancer.org/acs/groups/content/@epidemiologysurveillance/documents/document/acspc-031941.pdf>
 53. “Treatment Investigational New Drugs (INDs) Allowed to Proceed, June 22, 1987 – February 19, 2002,” Food and Drug Administration, <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/UCM117952.pdf>; One reason for the low number of treatment INDs is that many companies lack the funds or production capacity to manufacture a large quantity of the investigational drug to treat a large group of patients under a treatment IND. Those same companies, however, may be willing and able to supply individual patients on a case-by-case basis.
 54. “Physician Request for an Individual Patient IND under Expanded Access for Non-emergency or Emergency Use” Food and Drug Administration, February 13, 2012, <http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/InvestigationalNewDrugINDApplication/ucm107434.htm>
 55. Federal Register, Volume 74 Issue 155, August 13, 2009, <http://www.gpo.gov/fdsys/pkg/FR-2009->

08-13/html/E9-19005.htm

56. "Investigational New Drug Application (IND)," Department of Health and Human Services, Food and Drug Administration, <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083533.pdf>
57. "Physician Request for an Individual Patient IND under Expanded Access for Non-emergency or Emergency Use," Food and Drug Administration, February 13, 2012, <http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/InvestigationalNewDrugINDApplication/ucm107434.htm>
58. Judy Stone, "The s**t hits the fan – FDA, INDs, and fecal microbiota transplants," *Scientific American*, May 20, 2013, <http://blogs.scientificamerican.com/molecules-to-medicine/2013/05/20/the-st-hits-the-fan-fda-inds-and-fecal-microbiota-transplants/>
59. 21 CFR 312.40
60. Testimony of Michael A. Friedman, M.D., Lead Deputy Commissioner, Food and Drug Administration, "Providing Access to Promising Therapies for Seriously Ill and Dying Patients," U.S. House of Representatives Committee on Government Reform and Oversight, April 22, 1998, <http://www.fda.gov/NewsEvents/Testimony/ucm115120.htm>; FOIA response from the FDA regarding expanded access protocols on file with author.
61. Id.
62. "Trends, Charts, and Maps," National Institutes of Health, August 18, 2013, <http://clinicaltrials.gov/ct2/resources/trends>
63. FOIA response from the FDA regarding expanded access protocols on file with author. In April 2013, the Goldwater Institute sent a FOIA request to the FDA requesting a list of all applications for individual INDs since 2007, the name of the drug, device, or biologic being requested, and the final decision of the FDA. The FOIA request was routed to three different departments – the Center for Drug Evaluation and Research (CDER), the Center for Biologics Evaluation and Research (CBER), and the Center for Devices and Radiological Health (CDRH). To decrease the response time, at the request of the FDA, the Goldwater Institute dropped the request for the name of the drug, device, or biologic. Despite this, the FDA's response to the FOIA request was well beyond the statutory 20-day response period. In fact, no response has yet been received from CDRH despite multiple communications. The results from both CDER and CBER, however, reveal two issues. First, the number of individual IND requests is very small. Second, the FDA approves the vast majority of individual IND requests. Over an eight-and-a-half-year period, CBER received a mere 498 individual requests and granted all but five. The window of time that CDER was able to provide was more limited. For the three-year period that CDER was able to provide, the FDA received 1,634 individual patient IND requests and again approved almost all. As mentioned above, no results have yet been received from CDRH.
64. "Cancer Facts & Figures 2010" American Cancer Society, <http://www.cancer.org/acs/groups/content/@nho/documents/document/acspc-024113.pdf>
65. FOIA response on file with the author
66. "Clinical Trial Facts & Figures," The Center for Information & Study on Clinical Research Participation (CISCRP), http://www.ciscrp.org/professional/facts_pat.html
67. While the eligibility criteria vary from trial to trial, common eligibility standards include age, stage of the disease progression, medical history, prohibition on other co-morbidity patterns, etc.
68. The FDA regulation of the procedure began when the FDA determined that fecal microbiota was a biologic product.
69. "Clostridium difficile Infection," Center for Disease Control, updated March 1, 2013, http://www.cdc.gov/hai/organisms/cdiff/cdiff_infect.html
70. Els van Nood, M.D., et. al., "Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile," *New England Journal of Medicine*, January 31, 2013, <http://www.nejm.org/doi/full/10.1056/NEJMoa1205037>
71. Kristina Fiore, "Fecal Transplant: FDA Wants Regulation," *MedPage Today*, May 15, 2013, <http://>

- www.medpagetoday.com/InfectiousDisease/GeneralInfectiousDisease/39169
72. JoNel Aleccia, “Fecal Transplants may stall as FDA cracks down on docs,” *NBC News*, June 4, 2013, <http://www.nbcnews.com/health/fecal-transplants-may-stall-fda-cracks-down-docs-6C10186667>
 73. Beth Mole, “FDA Comes to Grips with Fecal Transplants,” *Scientific American*, June 12, 2013, <http://www.scientificamerican.com/article.cfm?id=fda-comes-to-grips-with-fecal-transplants>
 74. Aleccia, “Fecal Transplants may stall as FDA cracks down on docs.”
 75. 21 CFR 312.30; “Guidance for Industry: Expanded Access to Investigational Drugs for Treatment Use – Qs & As,” Food and Drug Administration, May 2013, <http://www.fda.gov/downloads/Drugs/.../Guidances/UCM351264.pdf>
 76. Fiore, “Fecal Transplant: FDA Wants Regulation.”
 77. Aleccia, “Fecal Transplants may stall as FDA cracks down on docs.”
 78. Aleccia, “FDA backs away from new fecal transplant rules.”
 79. “Guidance for Industry: Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies,” Food and Drug Administration, July 18, 2013, <http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm361379.htm>
 80. Id.
 81. Testimony of Michael A. Friedman, M.D., Lead Deputy Commissioner, Food and Drug Administration, “Providing Access to Promising Therapies for Seriously Ill and Dying Patients,” U.S. House of Representatives Committee on Government Reform and Oversight, April 22, 1998, <http://www.fda.gov/NewsEvents/Testimony/ucm115120.htm>
 82. “A National Survey of Orthopedic Surgeons Regarding the Food and Drug Administration and the Availability of New Therapies,” Competitive Enterprise Institute, 2007, <http://cei.org/sites/default/files/The%20Polling%20Company%20-%20A%20National%20Survey%20of%20Orthopedic%20Surgeons%20Regarding%20the%20Food%20and%20Drug%20Administration%20and%20the%20Availability%20of%20New%20Therapies.pdf>
 83. Sandra Williams, “Clinical Trials Recruitment and Enrollment: Attitudes, Barriers, and Motivating Factors,” 2004, http://cro.rbhs.rutgers.edu/documents/clinical_trials_recruitment_and_enrollment.pdf
 84. 21 USC 360bbb(b)
 85. Testimony of Dr. Michael A. Friedman, Lead Deputy Commissioner of the Food and Drug Administration on providing access to promising therapies for seriously ill and dying patients before the House Committee on Government Reform and Oversight, April 22, 1998, <http://www.fda.gov/NewsEvents/Testimony/ucm115120.htm>
 86. “How About a ‘Kianna’s Law’?” *Wall Street Journal*, March 24, 2005, <http://online.wsj.com/news/articles/SB111163190273988429>
 87. Testimony of Dr. Michael A. Friedman, Lead Deputy Commissioner of the Food and Drug Administration on providing access to promising therapies for seriously ill and dying patients before the House Committee on Government Reform and Oversight, April 22, 1998, <http://www.fda.gov/NewsEvents/Testimony/ucm115120.htm>
 88. “Guidance for Industry: Expanded Access to Investigational Drugs for Treatment Use – Qs & As,” Food and Drug Administration, May 2013, <http://www.fda.gov/downloads/Drugs/.../Guidances/UCM351264.pdf>
 89. Catherine Arnst, “Dying Patients Fight the FDA,” *Business Week*, July 25, 2007, <http://www.businessweek.com/stories/2007-07-25/dying-patients-fight-the-fda>*businessweek-business-news-stock-market-and-financial-advice*
 90. Jonathan Agin, “The Patient Choice Act – Providing Choice Instead of Death,” Huffington Post, May 2, 2013, http://www.huffingtonpost.com/jonathan-agin/the-patient-choice-act-providing-choice_b_3197669.html
 91. Testimony of Dr. Michael A. Friedman, Lead Deputy Commissioner of the Food and Drug Administration on providing access to promising therapies for seriously ill and dying patients before

- the House Committee on Government Reform and Oversight, April 22, 1998, <http://www.fda.gov/NewsEvents/Testimony/ucm115120.htm>
92. Id.
 93. “Guidance for Industry: Expanded Access to Investigational Drugs for Treatment Use – Qs & As,” Food and Drug Administration, May 2013, <http://www.fda.gov/downloads/Drugs/.../Guidances/UCM351264.pdf>
 94. Richard Klein, “Expanded Access Programs” Food and Drug Administration, Office of Special Health Issues, March 1, 2012, <http://www.fda.gov/downloads/ForIndustry/DevelopingProductsforRareDiseasesConditions/OOPDNewsArchive/UCM294794.pdf>
 95. Sandra Williams, “Clinical Trials Recruitment and Enrollment: Attitudes, Barriers, and Motivating Factors,” 2004, http://cro.rbhs.rutgers.edu/documents/clinical_trials_recruitment_and_enrollment.pdf
 96. Additionally, there may be a monetary incentive to enroll in a clinical trial where the investigational drug is provided at no cost to the patient while expanded access patients may incur costs.
 97. Andrew Von Eschenbach and Ralph Hall, “FDA Approvals Are a Matter of Life and Death,” *Wall Street Journal*, June 17, 2012, <http://online.wsj.com/article/SB10001424052702303753904577454163076760768.html>; For more information on proposed alternatives or reforms to the clinical trial process, see <http://news.heartland.org/newspaper-article/bold-proposal-fda-reform> and http://www.manhattan-institute.org/html/fda_05.htm
 98. 21 CFR 56.107
 99. 21 CFR 56.103
 100. 21 CFR 56.108(c)
 101. Id.
 102. “SACHRP Recommendations on Single Patient Treatment Use,” Secretary’s Advisory Committee on Human Research Protections, February 2012, <http://www.hhs.gov/ohrp/sachrp/mtgings/2012%20Feb%20Mtg/treatmentofuserecommendation.pdf>
 103. Id.
 104. Joint Letter to FDA Commissioner von Eschenbach from the American Pharmacists Association, the National Community Pharmacists Association, the National Alliance of State Pharmacy Association, the International Academy of Compounding Pharmacists, and the American College of Apothecaries, November 17, 2008, <http://www.ncpanet.org/pdf/letter-compoundingfdacorres20081117.pdf>
 105. “Guidance for Industry: Expanded Access to Investigational Drugs for Treatment Use – Qs & As,” Food and Drug Administration, May 2013, <http://www.fda.gov/downloads/Drugs/.../Guidances/UCM351264.pdf>
 106. “Planets Align to Allow Transplant,” *The Cutting Edge*, Johns Hopkins, Summer 2007, <http://www.hopkinsmedicine.org/surgery/edge/CuttingEdgeSUM07.pdf>
 107. Id.
 108. “Drug treatment Omegaven that could save infant’ lives not yet approved by the FDA” NBC News, June 7, 2013, http://rockcenter.nbcnews.com/_news/2013/06/07/18833434-drug-treatment-omegaven-that-could-save-infants-lives-not-yet-approved-by-fda
 109. Id.
 110. Id.
 111. Dr. David Gratzler, *The Cure: How Capitalism Can Save American Health Care* (New York: Encounter Books, 2008).
 112. Henry I. Miler, “The FDA at 100,” *Medical Progress Today*, July 6, 2006, http://www.medicalprogresstoday.com/enewsletters/mpt_ind.php?pid=1293&nid=0
 113. Opening Statement of Congressman Dan Burton, Committee Chairman, “Hearing on Compassionate Use of Investigational New Drugs: Is the Current Process Effective?” House Committee on Government Reform, June 20, 2001, <http://www.gpo.gov/fdsys/pkg/CHRG-107hhr77088/html/CHRG-107hhr77088.htm>
 114. Examples of recent attempts at reform at the federal level include the 2008 Access, Compassion, Care, and Ethics for Seriously Ill Patients Act (S. 3046), the 2010 Compassionate Access Act (H.R.

4732), the 2011 Access to Medical Treatment Act (H.R. 2736), and the 2012 Compassionate Freedom of Choice Act (H.R. 6342).

115. The full text of Right to Try is located in Appendix A
116. Right To Try Act, Section A(2)
117. Right To Try Act, Section B
118. Right To Try Act, Section C
119. See Appendix A for a full text of Right to Try.
120. Right to Try, Section B(1)
121. Right to Try, Section B(2)
122. Right to Try, Section B(3)
123. Right to Try, Section B(4)
124. Right to Try, Section C
125. "A National Survey of Orthopedic Surgeons Regarding the Food and Drug Administration and the Availability of New Therapies," Competitive Enterprise Institute, 2007, <http://cei.org/sites/default/files/The%20Polling%20Company%20-%20A%20National%20Survey%20of%20Orthopedic%20Surgeons%20Regarding%20the%20Food%20and%20Drug%20Administration%20and%20the%20Availability%20of%20New%20Therapies.pdf>
126. Right to Try, Section C
127. Right to Try, Section E
128. *Loving v. Virginia*, 388 U.S. 1 (1967); *Griswold v. Connecticut*, 381 U.S. 479 (1965); *Roe v. Wade*, 410 U.S. 113 (1973); *Moore v. East Cleveland*, 431 U.S. 494 (1977); *Meyer v. Nebraska*, 262 U.S. 390 (1923).
129. *Doe v. Bolton*, 410 U.S. 179, 218 (1973) (Douglas, J. concurring).
130. Edie Bacon, "My Life's Not FDA-Approved," *Wall Street Journal*, November 29, 2002, <http://online.wsj.com/article/0,,SB1038535925179938868.djm,00.html>
131. Thomas Jefferson, "Declaration of Independence" http://www.archives.gov/exhibits/charters/declaration_transcript.html